In commercial 35–42-day weaning transitions, the dominant production risk for Baizhu powder in swine feed premix is not chemical instability but flash mixer dead zones and marker loss during steam conditioning. A 10:1 aqueous extract of Atractylodis Macrocephalae Rhizoma is introduced after tracer studies in a 500 kg double-ribbon mixer demonstrate a relative standard deviation of ≤ 5.0% at a fill level of 55–65% v/v and rotor speed of 22–28 rpm. The pre-blend is formulated with 8–12% maize starch as flow modifier and 2–3% colloidal silicon dioxide to reduce hygroscopic caking when ambient relative humidity exceeds 60%. Addition ratio is fixed at 0.2–0.5% w/w of final complete feed only when the extract lot has a batch-specific atractylenolide III assay by HPLC; unstandardised raw rhizome powder should be confined to screening work at 0.5–1.5% w/w because lot-to-lot variation in polysaccharide and lactone content shifts dietary exposure. Published data for this specific configuration is limited, and the loading must be revalidated against the certificate of analysis before release. Industry compliance draws on the Chinese Veterinary Pharmacopoeia 2020 edition monograph where applicable, ISO 22000:2018 for feed-chain traceability, ISO/TS 22002-6:2016 for feed prerequisite programmes, ISO 16050:2003 for aflatoxin B1 screening, and ISO 6579-1:2017 for Salmonella detection. The downstream process uses a hammermill fitted with a 0.8–1.0 mm screen after pre-blending, followed by steam conditioning at 70–75°C for 25–30 s and pelleting at a die compression ratio of 1:8–1:10. Terminal heat exposure above 80°C is avoided because atractylenolide III recovery is temperature-dependent; if conditioning must exceed 80°C, post-pellet marker recovery by HPLC must be confirmed at pilot scale before release. Terminal dosage forms are granular complete feed, 1–2% supplementary premix, and pelleted creep feed for the 21–42 day postpartum transition period.

Can Atractylenolide III and Polysaccharide Marker Compounds Remain Intact During High-Speed Capsule Filling and Tablet Compression?

Veterinary tablet and capsule formulations containing Baizhu powder as the sole herbal API or within multi-herb gastrointestinal support products require preformulation control of particle-size distribution because raw rhizome powder exhibits poor flow and hygroscopicity at room humidity above 60% RH. In a production rotary tablet press with 16–24 stations and turret speed of 25–40 rpm, the granulation is adjusted to a Carr index of 20–25% and a Hausner ratio below 1.35; failure to reach these values produces die fill variation beyond the ±5.0% uniformity limit referenced in USP <905> and Ph. Eur. 2.9.5. The formulation addition ratio for compressed tablets is conventionally 15–25% w/w of a 5:1 dry Baizhu extract, with microcrystalline cellulose at 20–30%, lactose monohydrate or dicalcium phosphate at 15–25%, croscarmellose sodium at 2–5%, and magnesium stearate at 0.5–1.0%; these are starting ranges for an excipient compatibility design-of-experiments, and published data for this specific configuration is limited. Non-sterile veterinary dosage forms follow Ph. Eur. 2.6.12/2.6.13 or USP <61>/<62> for microbial examination, USP <795> for extemporaneous nonsterile preparation, and ICH Q3D elemental impurity limits where export dossiers require elemental screening. Downstream production begins with wet granulation using purified water or 2–5% povidone K30 solution, wet mass screening through a #14 mesh, fluid-bed drying at 50–60°C to moisture ≤ 5.0% w/w, and dry screening through #20 mesh before lubrication. Tablets are compressed to hardness of 60–90 N and tested for disintegration in water at 37°C using the basket apparatus of Ph. Eur. 2.9.1 or USP <701>, with a conventional acceptance limit of ≤ 15 min for uncoated botanical tablets. Capsule products are prepared by direct encapsulation after dry granulation when the extract is spray-dried with 5–10% maltodextrin; terminal dosage forms include 100–500 mg oral tablets, hard gelatin capsules, and flavoured oral pastes for cats and dogs. Water activity must remain below 0.60, as described in USP <1112>, to prevent extract softening, microbial growth, and capsule shell deformation in aluminium-PVC blister packaging.

At the point of oral fluid administration, the limiting variable is not the marker content of Atractylodis Macrocephalae Rhizoma but the suspended solids behaviour in dosing pump lines and nipple drinker manifolds. In poultry houses fitted with proportioning medicators set to 1:50 or 1:128, a concentrated stock suspension is prepared by dispersing a 10:1 extract in water at 35–40°C with 0.1–0.2% w/v polysorbate 80 as wetting agent and 0.05–0.1% w/v xanthan gum as suspending agent. The final drinking water concentration in this route is 0.05–0.20% w/v for a 10:1 extract, equivalent to 0.5–2.0 g/L; this range is operational screening data, not a regulatory dose claim, and must be adjusted to target species, water consumption, and lot-specific marker content. Industry compliance for an oral solution or suspension in food-producing animals falls under Regulation (EU) 2019/6 where the product is marketed as veterinary medicinal, or under Regulation (EC) 183/2005 where it is incorporated as a complementary feed liquid; microbial limits follow Ph. Eur. 2.6.12/2.6.13, and absence of Escherichia coli is verified by ISO 16649-2:2001. The downstream production process uses a high-shear disperser at 3,000–5,000 rpm for 20–30 min to break agglomerates, then a basket mill or inline colloid mill to reduce oversize particles to a D90 < 75 µm; the suspension is passed through a 150 µm in-line strainer before packaging. Terminal dosage forms are oral suspension in 1 L or 5 L high-density polyethylene bottles, oral drench solutions for calves, and bulk liquid concentrate for farm-side dosing pumps. If the suspension is stored in still tanks, bridging occurs; continuous low-shear agitation at 10–20 rpm in the holding tank is required until packaging to prevent nozzle blockage and dose non-uniformity.

Sterile Aqueous Injection of Atractylodes Macrocephala Polysaccharide: Pyrogen Removal, Filtration Flux, and Terminal Sterility Boundaries

Before an injectable presentation is considered, the veterinary manufacturer must confirm that the incoming powder is a low-endotoxin water-soluble fraction, not simple crude rhizome powder; the raw botanical material alone is not suitable for parenteral manufacture. The extraction intermediate should be a depyrogenated aqueous fraction with specified polysaccharide content and moisture ≤ 3.0% w/w. The final aqueous injection formula is typically prepared at 0.1–0.3% w/v polysaccharide extract, with sodium chloride added to 0.9% isotonicity and pH adjusted to 5.5–6.5 using dilute hydrochloric acid or sodium hydroxide. Published data for this specific configuration is limited; therefore, formulation must be justified through stability-indicating HPLC and gel-permeation chromatography profiles rather than historical monograph claims alone. Regulatory compliance for a sterile veterinary injectable follows EU GMP Annex 1 for terminal sterilisation or aseptic processing, Ph. Eur. 2.6.1 for sterility, Ph. Eur. 2.6.14 for bacterial endotoxins, and Ph. Eur. 5.1.10 for endotoxin limit derivation; sub-visible particulate matter is controlled under Ph. Eur. 2.9.19. The downstream process requires dissolution in Water for Injections at 40–50°C, passage through a 0.45 µm prefilter, and then a 0.22 µm sterilising-grade filter into depyrogenated vials. Terminal steam sterilisation at 121°C for 15 min may be employed only if stress studies confirm no loss of polysaccharide molecular weight and no colour change greater than 1.0% relative to unsterilised control; if heat-labile fractions are present, aseptic filtration is required. In that case, viscosity must not exceed 10–15 mPa·s at 25°C or filtration flux may collapse. Depyrogenation before final formulation uses tangential flow filtration with a 100 kDa membrane. Terminal dosage forms are 10 mL and 50 mL injectable solutions in Type I glass vials, or 20 mL multi-dose vials with an appropriate antimicrobial preservative only where multi-dose use is permitted for the target species. Incompatibility arises with oxidising agents and with pH below 4.0, where polysaccharide precipitation and filter blinding are observed.

In multi-herb veterinary powders where Baizhu powder is one of five to eight botanical ingredients, the highest process risk is segregation during high-speed sacheting and loss of granule hardness during bottle filling. The powder blend is typically prepared at 8–15% w/w of the total formula on a dried-herb equivalent basis; this ratio is derived from traditional formula proportions and is not a stand-alone therapeutic loading, so published data for this specific configuration is limited and ratio selection must be tied to the full formulation. Industry compliance is defined by the Chinese Veterinary Pharmacopoeia 2020 edition where a listed powder is manufactured, ISO 22000:2018 for cross-contamination control, and PIC/S GMP or local GMP for multi-herb veterinary powder lines where applicable. The downstream process uses low-shear ribbon mixing, hammermilling to pass 80 mesh, wet granulation in a high-shear granulator at impeller speed of 200–300 rpm and chopper speed of 1,500–2,500 rpm with 5–10% aqueous starch paste as binder, and fluid-bed drying at 60–70°C to loss-on-drying ≤ 5.0%. Sachet fill weight is controlled to ±5.0% on a multi-lane stick-pack machine with auto-rejection against the target fill. Terminal dosage forms are oral powders for large animals, granular sachets for piglets and poultry, and multi-herb premix powders intended for on-farm mixing or veterinary dispensing.